Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics

Prothena Corporation plc - Ordinary Shares (PRTA): $22.59

0.12 (+0.53%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add PRTA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#257 of 339

in industry

PRTA Price/Volume Stats

Current price $22.59 52-week high $73.14
Prev. close $22.47 52-week low $18.69
Day low $21.99 Volume 397,200
Day high $22.88 Avg. volume 668,939
50-day MA $21.28 Dividend yield N/A
200-day MA $29.79 Market Cap 1.21B

PRTA Stock Price Chart Interactive Chart >


Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio


Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.


PRTA Latest News Stream


Event/Time News Detail
Loading, please wait...

PRTA Latest Social Stream


Loading social stream, please wait...

View Full PRTA Social Stream

Latest PRTA News From Around the Web

Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Prothena Corp PLC Chief Accounting Officer Sells Company Shares

Karin Walker, Chief Accounting Officer of Prothena Corp PLC (NASDAQ:PRTA), sold 5,000 shares of the company on December 20, 2023, according to a recent SEC Filing.

Yahoo | December 21, 2023

These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank

Biotech is big business, no doubt about that. The healthcare sector takes up almost 1 in 5 dollars of the US gross domestic product, 18.3%, or approximately $13,000 per capita, according to data from the American Medical Association. The total sum is staggering – some $4.3 trillion. The US is the world leader in biomedical research, including innovation on new prescription drugs, medical devices, and other healthcare advances. The health sector R&D spend in the US comes to $250 billion annually.

Yahoo | December 17, 2023

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.

Yahoo | December 12, 2023

Alzheimer's Disease Space Evolves in 2023: Stocks in Focus

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Yahoo | December 11, 2023

Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Read More 'PRTA' Stories Here

PRTA Price Returns

1-mo 10.68%
3-mo 7.57%
6-mo -30.11%
1-year -68.00%
3-year -55.66%
5-year 125.90%
YTD -37.84%
2023 -39.68%
2022 21.96%
2021 311.32%
2020 -24.13%
2019 53.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!